Swiss National Bank Sells 24,300 Shares of OPKO Health, Inc. $OPK

Swiss National Bank cut its position in shares of OPKO Health, Inc. (NASDAQ:OPK) by 3.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 661,155 shares of the biotechnology company’s stock after selling 24,300 shares during the period. Swiss National Bank owned approximately 0.08% of OPKO Health worth $1,098,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in OPKO Health by 1.0% during the first quarter. Vanguard Group Inc. now owns 29,500,071 shares of the biotechnology company’s stock valued at $48,970,000 after buying an additional 293,740 shares during the last quarter. Millennium Management LLC lifted its stake in shares of OPKO Health by 85.3% in the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock valued at $6,745,000 after purchasing an additional 2,112,382 shares during the last quarter. Northern Trust Corp raised its holdings in shares of OPKO Health by 4.7% in the fourth quarter. Northern Trust Corp now owns 3,697,774 shares of the biotechnology company’s stock worth $5,436,000 after buying an additional 164,847 shares during the period. Lazard Asset Management LLC raised its holdings in shares of OPKO Health by 143.6% in the fourth quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock worth $3,746,000 after buying an additional 1,502,342 shares during the period. Finally, Y.D. More Investments Ltd raised its holdings in shares of OPKO Health by 27.0% in the first quarter. Y.D. More Investments Ltd now owns 1,772,947 shares of the biotechnology company’s stock worth $2,971,000 after buying an additional 377,179 shares during the period. 64.63% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on OPK. Barrington Research restated an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a report on Thursday, May 1st. Zacks Research upgraded OPKO Health from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 14th. LADENBURG THALM/SH SH upgraded OPKO Health to a “strong-buy” rating in a research note on Tuesday, July 8th. Finally, Wall Street Zen downgraded OPKO Health from a “hold” rating to a “sell” rating in a research note on Monday, May 5th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $2.75.

Insiders Place Their Bets

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 675,000 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was bought at an average cost of $1.32 per share, for a total transaction of $891,000.00. Following the completion of the transaction, the chief executive officer owned 214,676,448 shares of the company’s stock, valued at approximately $283,372,911.36. The trade was a 0.32% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 49.69% of the company’s stock.

OPKO Health Price Performance

NASDAQ:OPK opened at $1.39 on Tuesday. OPKO Health, Inc. has a 12 month low of $1.11 and a 12 month high of $2.0350. The stock has a 50 day moving average of $1.33 and a two-hundred day moving average of $1.46. The company has a current ratio of 3.41, a quick ratio of 3.02 and a debt-to-equity ratio of 0.25. The firm has a market cap of $1.10 billion, a P/E ratio of -5.56 and a beta of 1.19.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The firm had revenue of $156.80 million for the quarter, compared to analysts’ expectations of $165.74 million. OPKO Health had a negative return on equity of 13.17% and a negative net margin of 26.68%.OPKO Health’s quarterly revenue was down 13.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.01) earnings per share. On average, analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.